SCHEMBL17668342

SCHEMBL17668342

CC1CCN(S(=O)(=O)NC(=O)c2ccccc2)CC1

nearest known ligand 0.55

Predicted protein targets (top 16)

geneUniProtsupporting neighboursconfidence
ACHE P22303 1/20 0.53
HRH1 P35367 2/20 0.51
CCR3 P51677 2/20 0.51
KCNH2 Q12809 2/20 0.51
KMT2A Q03164 6/20 0.50
MEN1 O00255 3/20 0.50
NPC1 O15118 1/20 0.49
ALDH1A1 P00352 4/20 0.49
KDM4E B2RXH2 1/20 0.49
LMNA P02545 5/20 0.48
TSHR P16473 1/20 0.46
HTT P42858 1/20 0.46
SMN1; SMN2 Q16637 1/20 0.46
MAPT P10636 1/20 0.46
MAPK1 P28482 1/20 0.46
HSD17B10 Q99714 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL31535075 0.83 POLB (0.57) HRH1CCR3KCNH2KMT2AMEN1
SCHEMBL31680887 0.82 SMN1; SMN2 (0.56) HRH1CCR3KCNH2KMT2AMEN1
SCHEMBL28843872 0.81 POLB (0.60) KMT2AMEN1NPC1ALDH1A1KDM4E
SCHEMBL6649340 0.79 KMT2A (0.56) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL28138491 0.75 HTT (0.65) ACHEKMT2AALDH1A1HTTSMN1; SMN2
SCHEMBL31535491 0.72 POLB (0.49) KMT2AMEN1ALDH1A1KDM4ELMNA
SCHEMBL32679522 0.71 KMT2A (0.72) KMT2AMEN1ALDH1A1LMNAMAPT
SCHEMBL2153314 0.71 ALDH1A1 (0.71) ACHEKMT2ANPC1ALDH1A1LMNA
SCHEMBL26975371 0.70 NLRP3 (0.51)
SCHEMBL15690659 0.70 HTT (0.63) ACHEKMT2AMEN1ALDH1A1KDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20160101074-A1 SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION PHILADELPHIA HEALTH & EDUCATION CORPORATION D/B/A DREXEL UNIVERSITY COLLEGE OF MEDICINE 2016-04-14 US claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160101074-A1 SULFAMOYLBENZAMIDE DERIVATIVES AS ANTIVIRAL AGENTS AGAINST HBV INFECTION ALKBH5, SULT1A1, SHMT1 ACHE 2904/4885HRH1 3766/4885CCR3 2251/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.